QNRX QUOIN PHARMACEUTICALS LTD

Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET

Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET

ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2023 financial results after the market closes on Wednesday, August 2, 2023.

The Company will host a conference call and webcast at 8:30am ET on Thursday, August 3, 2023. The call will include a discussion of second quarter 2023 financial results and a corporate update.

The live call can be accessed by dialing 1-800-603-0527 (domestic) or 1-412-317-0688 (international).

The live and archived webcast of the call will also be available on the Quoin Pharmaceuticals website under the Investors section or by following this link:

About Quoin Pharmaceuticals Ltd.



Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit:  or  for updates.

For further information, contact:

Investor Relations

PCG Advisory

Stephanie Prince



(646) 863-6341



EN
27/07/2023

Underlying

QNRXQUOIN PHARMACEUTICALS LTD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUOIN PHARMACEUTICALS LTD

 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Profe...

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases New episode spotlights the severe burden of Netherton Syndrome in infants and children, reinforcing the need for effective pediatric treatments ASHBURN, Va., June 26, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the release of a new episode in its NETHERTON NOW video series. The episode features ...

June 26, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Desi...

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the Company’s lead asset, QRX003, for the treatment of Netherton Syndrome. The designation reinforces the potential of QRX003 as a therapeutic candidat...

June 24, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivot...

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study Study CL-QRX003-002 will test whole-body application of QRX003 in conjunction with off-label systemic therapy in approximately 12-15 subjects.Study CL-QRX003-002 complements first whole-body pivotal study, CL-QRX003-003, being led by Dr. Amy Paller at Northwestern University and supported by up to six international sites that are expected to open, where subjects are being tested with QRX003 as monotherapy. Combined data from Studies CL-QRX003-002 and CL-QRX003-003 is ...

May 22, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants...

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces that it has been granted Orphan Dru...

May 20, 2025 1 EN
 PRESS RELEASE
Free
QNRX QUOIN PHARMACEU...

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX...

Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study Clear Improvement in Patient’s Skin Appearance Observed in Study after 12 weeks Compared to BaselineKey endpoints including Investigator’s Global Assessment (IGA), Modified Ichthyosis Area Severity (M-IASI) and Children’s Dermatology Life Quality Index (CDLQI) all demonstrated improvement from baseline QRX003 is being well tolerated and no adverse events have been reportedPatient is expected to continue to be treated with QRX003 to assess progressCompany continues to advance ...

May 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch